目的 探討慢性前列腺炎患者使用歸柏化瘀膠囊聯(lián)合鹽酸坦索羅辛緩釋膠囊治療的臨床療效。方法 選取2021年1月—2023年6月淮南新華醫(yī)療集團(tuán)新華醫(yī)院收治的130例慢性前列腺炎患者，按隨機(jī)抽簽法將患者隨機(jī)分為對(duì)照組和治療組，每組各65例。對(duì)照組口服鹽酸坦索羅辛緩釋膠囊，0.2 mg/次，1次/d。治療組在對(duì)照組基礎(chǔ)上口服歸柏化瘀膠囊，3粒/次，3次/d。兩組均持續(xù)治療4周。比較兩組臨床療效、慢性前列腺炎癥狀指數(shù)（NIH-CPSI）評(píng)分、前列腺體積、前列腺移行區(qū)體積、尿流動(dòng)力學(xué)指標(biāo)、前列腺液炎性因子水平。結(jié)果 治療組的總有效率為95.38%，較對(duì)照組的總有效率83.08%高（P<0.05）。治療后，兩組疼痛評(píng)分、排尿障礙評(píng)分、生活質(zhì)量評(píng)分、NIH-CPSI總分均低于治療前（P<0.05），且治療組的疼痛評(píng)分、排尿障礙評(píng)分、生活質(zhì)量評(píng)分、NIH-CPSI總分低于對(duì)照組（P<0.05）。治療后，兩組前列腺體積、前列腺移行區(qū)體積均低于治療前（P<0.05），且治療組的前列腺體積、前列腺移行區(qū)體積低于對(duì)照組（P<0.05）。治療后，兩組最大尿流率（MFR）、平均尿流率（AFR）高于治療前，膀胱殘余尿量（PVR）低于治療前（P<0.05），且治療組MFR、AFR高于對(duì)照組，PVR低于對(duì)照組（P<0.05）。治療后，兩組患者前列腺液腫瘤壞死因子-α(TNF-α)、白細(xì)胞介素-6(IL-6)、白細(xì)胞介素-8(IL-8)水平均顯著降低（P<0.05），且治療組的前列腺液TNF-α、IL-6、IL-8水平較對(duì)照組降低更顯著（P<0.05）。結(jié)論 歸柏化瘀膠囊聯(lián)合鹽酸坦索羅辛緩釋膠囊治療慢性前列腺炎患者，可減輕炎癥反應(yīng)，促進(jìn)前列腺恢復(fù)，改善尿流動(dòng)力學(xué)，控制病情程度。

Objective To investigate the therapeutic effect of Guibai Huayu Capsules combined with Tamsulosin Hydrochloride Sustained-release Capsules in treatment of chronic prostatitis. Methods 130 Patients with chronic prostatitis admitted to Xinhua Hospital of Huainan Xinhua Medical Group from January 2021 to June 2023 were selected as the study objects, and randomly divided into control group and treatment group according to random drawing method, with 65 cases in each group. Patients in the control group took orally Tamsulosin Hydrochloride Sustained-release Capsules at a dose of 0.2 mg/time, once daily. Patients in the treatment group were given Guibai Huayu Capsules orally on the basis of the control group, 3 capsules/time, 3 times daily. Patients in both groups continued treatment for 4 weeks. The clinical efficacy, NIH-CPSI score, prostate volume, prostate transitional zone volume, urinary flow dynamics index, and prostatic fluid inflammatory factor were compared between two groups. Results The total effective rate of treatment group was 95.38%, which was higher than 83.08% of control group（P＜0.05）. After treatment, the pain score, voiding disorder score, quality of life score, and NIH-CPSI total score of both groups were lower than those before treatment（P＜0.05）, and the pain score, voiding disorder score, quality of life score, and NIH-CPSI total score of the treatment group were lower than those of the control group（P＜0.05）. After treatment, the prostate volume and the transitional zone volume of prostate in two groups were lower than those before treatment（P＜0.05）, and the prostate volume and the transitional zone volume of prostate in the treatment group were lower than those in the control group（P＜0.05）. After treatment, maximum urinary flow rate（MFR） and average urinary flow rate（AFR） of the two groups were increased, but residual urinary volume（PVR） of the two groups was decreased（P＜0.05）. And MFR and AFR of the treatment group were higher than those of the control group, but PVR was lower than those of the control group（P＜0.05）. After treatment, the levels of tumor necrosis factor-α（TNF-α）, interleukin-6（IL-6）, and interleukin-8（IL-8） in prostatic fluid of both groups were decreased（P＜0.05）, and the levels of TNF-α, IL-6, and IL-8 in prostatic fluid of the treatment group were significantly lower than those of the control group（P＜0.05）. Conclusion The combination of Guibai Huayu Capsules and Tamsulosin Hydrochloride Sustained-release Capsules in treatment of chronic prostatitis can reduce inflammatory response, promote the recovery of prostate volume, improve urine flow dynamics, and control the severity of disease.

R983

安徽省高校教學(xué)研究項(xiàng)目(2021ljyxm0385)